Multivalent Pneumococcal Conjugate Vaccine for Broad Serotype Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pneumococcal vaccines have low serotype coverage, poor immunogenicity, and potential immunosuppressive effects, necessitating the development of a multivalent vaccine that addresses a wider range of pathogenic serotypes with improved immunogenicity and reduced immunosuppression.
Innovation Solution
A multivalent immunogenic composition comprising capsular polysaccharides from various Streptococcus pneumoniae serotypes, conjugated to carrier proteins like CRM197 and TTD, with an adjuvant and surfactant, to induce a broad immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polysaccharide-protein conjugate vaccines use carrier proteins like CRM197 and TTD to improve immunogenicity, then immunogenicity is enhanced, but immunosuppressive effects increase
Solution Approach 1:
The patent divides the carrier protein function into separate components: CRM197 for immunogenicity enhancement and TTD for immunosuppression reduction. By segmenting the carrier protein roles and using specific serotype combinations (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, 33F), the vaccine achieves balanced immunogenicity while minimizing immunosuppressive effects through selective carrier protein assignment to specific polysaccharide components.
2Adaptability or versatility
If existing polysaccharide conjugate vaccines cover limited serotypes (PCV10: 52.3%, PCV13: 68.4%), then vaccine formulation is simplified, but serotype coverage is insufficient
Solution Approach 1:
The patent segments the pneumococcal polysaccharide components into 11 specific serotypes (2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, 33F) that are most prevalent and pathogenic. This segmentation approach provides comprehensive coverage of major serotypes while maintaining manageable vaccine formulation complexity through systematic organization of polysaccharide-protein conjugates.
Solution Approach 2:
The patent creates a universal multivalent vaccine formulation that simultaneously addresses multiple serotypes through a single vaccine product containing 11 different polysaccharide-protein conjugates. This multi-functional approach provides broad serotype coverage (68.4% to 70% of all pneumococcal serotypes) while simplifying administration compared to multiple separate vaccines.
3Reliability
If polysaccharide-protein conjugate vaccines use high doses or repeated use of carrier proteins to enhance immune response, then immunogenicity improves, but immunosuppression risk increases
Solution Approach 1:
The patent applies local quality by assigning specific carrier proteins to specific polysaccharide serotypes based on their individual immunogenicity profiles and immunosuppression risks. Not all serotypes use the same carrier protein; the formulation strategically selects CRM197 or TTD carriers for specific serotype combinations to optimize immune response while minimizing overall immunosuppression, creating localized optimization throughout the multivalent formulation.
Data Source
AI summary
The present invention relates to a polyvalent pneumococcal polysaccharide protein conjugate and immunogenicity thereof, and specifically provides an immunogenic composition containing capsular polysaccharides of Streptococcus pneumoniae from different serotypes, and a carrier, the serotypes at least comprising 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F and 33F. The immunogenic composition can improve the immunogenicity of polysaccharides of different serotypes, and may prevent invasive infection caused by pneumococci of various different serotypes.